Pathology of small airways disease.
CLASSIFICATIONS OF SMALL AIRWAYS DISEASE
Hogg and colleagues (21) in 1968 first used the term small airways disease to describe airway disease in patients with variably severe chronic airflow obstruction characterized by loss of bronchioles, mucus plugs, and variable amounts of inflammation and fibrosis that involve "the smallest bronchi as well as the bronchioles, so that neither bronchitis nor bronchiolitis is an appropriate term." Disease severity was noted to correlate with occlusion of airway lumen by mucus and inflammatory cells. (21) This original, limited definition of small airways disease by Hogg and colleagues has given way during the years to an expanded scope of diseases affecting the airways that are considered in various classification schemes as small airways disease. Because classifications of lung diseases are in some respects dynamic and overlapping, classifications of small airways disease vary. There have been several proposed classifications of small airways disease, including, for example, one of the initial classifications by Myers and Colby in 1993 (Table 1) and a relatively recent 2006 classification by Katzenstein (Table 2). (17,23,27,30,31) Another recent classification that is descriptive of the various pathologic patterns is listed in Table 3. One might classify these diseases according to whether the histologic patterns, along with clinical and radiologic correlation, show changes diagnostic of a particular disease; however, except for diffuse idiopathic neuroendocrine cell hyperplasia and diffuse panbronchiolitis, and arguably follicular bronchiolitis and respiratory bronchiolitis-interstitial lung disease, the histologic changes, such as cellular bronchiolitis and fibrotic changes, are typically not specific for a distinctive etiology. One could also classify small airways diseases for whether the disease is primary to the small airways or secondary to other lung disease, such as smoking or asthma. Ultimately, what classification scheme one prefers is less important than an understanding of the histologic features, the disease processes involved, the limitations of histologic diagnosis, and the confidence one can make a specific diagnosis on a biopsy of small airways disease.
EVALUATION OF BIOPSIES WITH SMALL AIRWAYS DISEASE
Although small airways diseases as a group are relatively common, many patients have straightforward clinical and radiologic diagnoses and are treated without biopsy confirmation of the disease. Pulmonologists performing bronchoscopy typically focus on biopsying discrete masses rather than diseases that involve a diffuse but relatively peripheral portion of the pulmonary airways. Features of the various small airways diseases overlap, and a firm diagnosis may not be possible on limited endobronchial or transbronchial biopsy tissue, and diagnoses are often descriptive rather than specifically diagnostic of a specific entity. Clinical and radiologic correlation is necessary to provide the most accurate diagnosis.
Small airways may be involved with disease primarily or may be involved secondarily by diseases primarily affecting bronchi or lung parenchyma. Although etiologies are numerous, small airways disease may be generally divided into small airways disease related to tobacco; to various other exposures, including mineral dusts; to diseases involving other areas of the lung, with secondary bronchiolar involvement; and to idiopathic causes. In some cases, small airways disease may be extremely subtle histologically and can be missed on examination. (22,24) Although occasionally small airways have been described with sizes other than less than 2 mm, (32) small airways are currently defined as airways having a diameter of less than 2 mm. (7,27,33-35) It is important to keep in mind that the less than 2-mm measurement is of luminal (ie, measuring from mucosa to mucosa) diameter. In terms perhaps more useful for the pathologist on a daily basis, the term small airways includes membranous bronchioles, respiratory bronchioles, and alveolar ducts (29,36) (Figures 1 and 2). Membranous bronchioles, bronchioles ranging from approximately 1 mm down to approximately 0.5 mm in diameter, normally contain a layer of smooth muscle and a layer of adventitia and are lined by ciliated columnar cells and Clara cells. Smooth muscle is diminished distally. They lack cartilage and may contain rare goblet cells or seromucinous glands. The final generation of membranous bronchiole is termed terminal bronchiole and opens into a functional unit of the lung termed an acinus, which is composed of respiratory bronchioles, alveolar ducts, and alveoli. Another functional unit, the lobule, is composed of approximately 3 to 10 acini, enclosed by an interlobular septum. Respiratory bronchioles have alveoli budding from their walls, the number of which increases distally. They are lined by columnar or simple cuboidal epithelium. (26) Small airways have been termed the lung's "Achilles heel" because of their importance in airflow and air distribution and their lack of bronchilike rigidity to protect them from collapsing during exhalation, especially when involved with disease. (37)
The following is a nonexhaustive review of the pathology of some of the small airways diseases, specifically cellular bronchiolitis, including follicular bronchiolitis and diffuse panbronchiolitis; granulomatous bronchiolitis; tobacco smoke-associated small airways bronchiolitic diseases, hypersensitivity pneumonitis; organizing pneumonia; constrictive bronchiolitis; mineral dust exposure and various other exposure-associated bronchiolitic diseases; and 4 recently described bronchiolitic disorders, bronchiolitic disease due to ingestion of Sauropus androgynus, airway-centered interstitial fibrosis, idiopathic bronchiolocentric interstitial pneumonia, and bronchiolitis interstitial pneumonitis.
The term bronchiolitis is a generic term used clinically to define a variety of inflammatory conditions involving the small airways. Bronchiolar and peribronchiolar inflammation may be focal or diffuse and may or may not be associated with scarring and bronchiolar metaplasia. Bronchiolar mucosa may undergo bronchiolar, squamous, or goblet cell metaplasia.
[FIGURE 1 OMITTED]
[FIGURE 2 OMITTED]
[FIGURE 3 OMITTED]
[FIGURE 4 OMITTED]
[FIGURE 5 OMITTED]
[FIGURE 6 OMITTED]
Bronchiolar-type epithelium that grows along the alveolar surfaces adjacent to bronchioles has been termed peribronchiolar metaplasia or lambertosis, in reference to the canals of Lambert through which bronchiolar epithelium was once considered to traverse to grow on alveolar septa (21,29,38-41) (Figures 3 and 4). Peribronchiolar metaplasia may be present in a variety of processes involving the small airways. Bronchiolarization may occur in the setting of healed bronchiolitis or interstitial fibrosis and may also be found in association with chronic hypersensitivity pneumonitis, constrictive bronchiolitis, or bronchiectasis. Idiopathic foci of peribronchiolar metaplasia may also be found; these may represent healed sites of prior infection or other localized injury.
The term cellular bronchiolitis describes disease in which the primary pattern is an inflammatory infiltrate within the bronchioles. The inflammatory infiltrate may be acute, chronic, or both acute and chronic and may or may not be associated with peribronchiolar fibrosis or metaplasia. (39,42)
Acute bronchiolitis is most commonly found in infants and young children. (43-65) It is the most common respiratory ailment during the first year of life. Its etiology is generally infectious, and although approximately three-fourths of cases are due to respiratory syncytial virus, numerous other infections may be causative, including other viruses such as measles, adenovirus, influenza, and parainfluenza; nonviral organisms such as fungi and mycoplasma; and Bordetella pertussis. * It occurs most frequently during the winter months. Infants often present with tachypnea, wheezing, and tachycardia, with more severely ill patients exhibiting chest retraction and nasal flaring. Lung hyperinflation is often found on x-ray. Some cases may show patchy ground glass opacities or small centrilobular nodules as well. High-resolution chest CT scan may show branching linear opacities or small centrilobular nodules. Focal areas of nodularity may be present, representing foci of bronchopneumonia. In obvious cases of acute bronchiolitis, chest radiology is more frequently being omitted. (3) Patients typically do not undergo open biopsy; however, biopsy may be obtained in some cases having unusual presentations. Histologically, acute bronchiolitis consists of bronchioles filled with necrotic debris and purulent exudative material, as well as sloughed bronchiolar mucosal cells. The residual bronchiolar mucosa and surrounding bronchiolar wall contain a neutrophilic infiltrate (23,24,39,66-72) (Figure 5). Most cases are treated symptomatically, with generally excellent prognosis. Rare cases exhibit long-term morbidity or mortality. In a small number of patients, long-term disease results in constrictive bronchiolitis. Drug treatments have not shown convincing benefit; however, oxygen is generally administered in cases with significant hypoxia. Home oxygen therapy is being more frequently used to reduce hospital stay. Also, corticosteroids have reportedly shown benefit in some patients with croup, and nebulized saline has been reported to reduce morbidity and length of hospital stay in patients with acute bronchiolitis. ([double dagger]) It is uncertain what factors contribute to disease severity in infants; however, cell-mediated immune response to disease pathogenesis has been implicated. Recent studies have estimated that 22% of cases in infants have a hereditary contribution to disease severity. Increased risk of severe acute respiratory syncytial virus bronchiolitis has been reported to correspond to a haplotype at the IL13-IL4 locus that is associated with increased interleukin (IL)-13 production. Interleukin-8 levels have been reported to correlate with length of hospitalization, and IL-8 associated airway inflammation has been reported to relate significantly to the severity of acute epidemic bronchiolitis. (45,51,65,66) Acute bronchiolitis in adults has a variety of potential causes, as listed in Table 4.
Acute and Chronic Bronchiolitis
Acute and chronic bronchiolitis is generally found in adults, and potential etiologies are numerous (Table 5). Although many cases are caused by infections, including respiratory syncytial virus, other noninfectious etiologies exist. Some cases are idiopathic. (23,24,39,45,66-72) Patients often have mild symptoms but may present with shortness of breath of variable duration, with or without cough. Pulmonary function tests may show an obstructive pattern. (68,71,72) Histologically, bronchiolar lumen contain purulent exudative material and sloughed bronchiolar mucosal cellular debris and variable amounts of mucus, and bronchiole mucosa and walls contain a mixed neutrophilic infiltrate and chronic inflammatory cell infiltrate made up predominantly of lymphocytes and plasma cells. The mixed acute and chronic inflammatory cell infiltrate extends into peribronchiolar tissue, and edema may be present. (23,24,39,67,68,71,72) In patients with disease caused by respiratory syncytial virus, various chemokines, including regulated upon activation, normal T cell expressed and secreted; IL-8; IL-1; and IL-6 have been implicated in recruitment and activation of inflammatory cells, including neutrophils, macrophages, lymphocytes, and eosinophils, to the infected area. (65,69,70,72) Most patients have a good prognosis with generally full recovery. Patients with idiopathic disease may show therapeutic response to antibiotics and immunosuppressive drugs; however, in these patients residual pulmonary impairment is frequent. (39,66,70-72)
Chronic bronchiolitis describes a histologic pattern in which bronchioles contain, and peribronchiolar tissues are infiltrated with, chronic inflammatory cells. Germinal centers and constrictive bronchiolitis may or may not be present, and if germinal centers predominate and constriction of the airway lumen is significant, the diagnosis of follicular bronchiolitis should be considered. The histologic features of acute and chronic bronchiolitis may overlap with chronic bronchiolitis. (24,39,71,72) Chronic bronchiolitis may be a feature of various diseases (Table 6) and may be idiopathic. (39,71,72) Fibrosis may or may not be present in association with chronic bronchiolitis. The presence of fibrosis suggests some amount of irreversibility of the process. Although chronic bronchiolitis with fibrosis is a common feature of chronic obstructive pulmonary disease, the lesion is rarely biopsied in that setting.
Histologically, bronchiolar necrosis describes mucosal necrosis and sloughing of mucosa into the airway lumen, with or without necrosis of the bronchiolar wall. (39) Bronchiolar necrosis may be identified in a variety of diseases, including infections (Table 7).
Follicular bronchiolitis consists of lymphoid hyperplasia of the bronchus-associated lymphoid tissue. (29,80-90) It is caused by altered immune response or immune stimulus of the bronchus-associated lymphoid tissue and is a feature of various immune-related disorders involving the lungs, including collagen vascular diseases, especially rheumatoid arthritis and Sjogren syndrome; bronchiectasis and middle lobe syndrome; hypersensitivity reactions; and various types of immune deficiency states such as AIDS and congenital immunodeficiency disorders. Some cases are idiopathic. (29,80-83,85-89,91-93) It has been reported to cause posttransplantation bronchiolitis obliterans syndrome. 84 Radiologic features include reticulonodular infiltrates or small nodules on chest x-ray. High-resolution CT scan may show peribronchial nodules, with or without patchy ground glass opacities. Histologically follicular bronchiolitis is characterized by peribronchiolar lymphoid hyperplasia that extends into surrounding lung parenchyma. Reactive germinal centers are present (29,72) (Figure 6). Therapy depends on the underlying causative process. Overall prognosis has been reported to be good. (29,39,83,84,90) Patients with idiopathic disease may benefit from steroids and bronchodilators. (72,80-83,93,94)
Eosinophilic bronchiolitis is characterized histologically by bronchiolar walls containing increased numbers of eosinophils. Its presence may be secondary to asthma or allergic bronchopulmonary aspergillosis, although patients with these diseases usually have increased eosinophils within bronchi rather than bronchioles. Eosinophilic pneumonia, drug reactions, and parasitic or fungal infections may also occasionally exhibit eosinophilic bronchiolitis, but there is usually a predominant interstitial disease component present. (95-99) One patient with a prior diagnosis of diffuse panbronchiolitis and worsening symptoms despite therapy subsequently was diagnosed as having eosinophilic bronchiolitis. (96)
Diffuse panbronchiolitis, an idiopathic, bilateral, progressive, obstructive, suppurative small airways disease associated with sinusitis, primarily occurs in Japan, has been increasingly identified within other Asian populations, and is uncommon in the United States. (29,100-126) The term diffuse panbronchiolitis refers to its distribution in both lungs (diffuse) and the inflammatory involvement of all layers of the wall or respiratory bronchioles (pan). (122) Because diffuse panbronchiolitis is predominantly found in Japan, a genetic predisposition is assumed to play a role in disease progression. Human leukocyte antigen alleles are thought to cause a genetic predisposition to diffuse panbronchiolitis. Researchers have shown an association with HLA-Bw (54), found predominantly among East Asians, and diffuse panbronchiolitis, with 63% of Japanese patients possessing the antigen compared with 11% of control subjects. Korean patients have been shown to have an association with HLA-A11. These findings suggest a major HLA susceptibility gene for diffuse panbronchiolitis. (122,126-130) Patients average approximately 40 years of age at presentation; however, there is a wide age range from the first to the seventh decades of life. Males predominate, with a male to female ratio in Japan reportedly between 1.4:1 and 2:1. No association with smoking or exposure to fumes or toxins has been proven. Patients typically present with a variable history of chronic sinusitis, cough, and dyspnea. Some patients may produce purulent sputum. Pulmonary function studies show obstructive changes. Radiographically, diffuse panbronchiolitis produces bilateral small nodules on x-ray and centrilobular lesions on high-resolution CT scan. ([section]) On biopsy, yellow bronchiolocentric nodules measuring approximately 1 mm to 3 mm are identified. Histologically, diffuse panbronchiolitis is characterized by transmural infiltration of the bronchiole and surrounding lung interstitium with foamy macrophages, plasma cells, and lymphocytes. The changes involve terminal bronchioles, respiratory bronchioles, and alveolar ducts. Predominantly respiratory bronchiole involvement is a distinctive feature of diffuse panbronchiolitis, as other forms of constrictive bronchiolitis predominantly affect membranous bronchioles. (122,133) Foamy macrophages and other inflammatory cells may fill the bronchiolar lumen and may involve alveolar spaces; however, alveoli are relatively spared in diffuse panbronchiolitis (Figure 7). Neutrophils may be identified in the bronchiolar lumen as well. Follicular bronchiolitis can occur as part of the histologic changes, and superimposed acute or organizing pneumonia and bronchiectasis may be present. Terminal bronchioles may become ectatic as the disease advances. Untreated disease generally progresses to bronchiectasis, with resultant respiratory failure and death. (122,125,126,134,135)
Patients typically have associated infections, and Pseudomonas infection is associated with a poor prognosis. Significantly improved survival has been reported in patients treated with chronic low-dose macrolide antibiotic therapy, with improved survival considered to be caused by the drug's antiinflammatory affects rather than its antibiotic properties. ** Diagnosis is generally made based on the disease's clinical, radiographic, and histologic features. Isolation from the sputum of Haemophilus influenza and Streptococcus pneumoniae, and in advanced stages of disease, Pseudomonas aeruginosa, assists in making the diagnosis. (122,126,134) Differential diagnosis includes xanthomatous bronchiolitis, rheumatoid arthritis-associated bronchiolitis and other collagen vascular disease and autoimmune diseases, human T-cell lymphotropic virus type 1-associated bronchiolitis, and idiopathic bronchiolitis. ([dagger])([dagger])
Granulomatous bronchiolitis is characterized histologically by granulomas within bronchiolar walls, with or without giant cells or necrosis (39) (Figure 8). Granulomatous bronchiolitis is a feature of a variety of pulmonary disorders (Table 8). (39,143-155) Clinical, radiologic, therapeutic, and prognostic features are those of the underlying disease. Although not diagnostic, well-formed noncaseating granulomas suggest sarcoidosis; caseating granulomas suggest infection; poorly formed nonnecrotizing granulomas, especially in association with interstitial lymphocytic infiltrates or organizing pneumonia, suggest hypersensitivity pneumonitis; and noncaseating granulomas with associated foreign body giant cells or foreign material suggest aspiration pneumonia.
ORGANIZING PNEUMONIA WITH INTRALUMINAL POLYPS (BRONCHIOLITIS OBLITERANS WITH INTRALUMINAL POLYPS) (FORMERLY TERMED BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA/ORGANIZING PNEUMONIA PATTERN)
Organizing pneumonia with intraluminal polyps, formerly termed bronchiolitis obliterans organizing pneumonia/ organizing pneumonia pattern, may occur secondary to a wide variety of lung injuries (Table 9). (29,39,156-186) It may also be idiopathic, termed cryptogenic organizing pneumonia, formerly termed idiopathic bronchiolitis obliterans organizing pneumonia. (44) Histologically, organizing pneumonia is characterized by plugs of granulation tissue, composed of fibroblasts within a myxoid or edematous stroma, which are located within bronchiolar lumens, alveolar ducts, and associated alveolar airspaces (Figure 9). Within airspaces, these plugs of granulation tissue may form rounded nodules, termed Masson bodies. A variable interstitial lymphocytic infiltrate may be present. If bronchiolar obstruction is a feature of the disease, foamy macrophages may be present within alveolar airspaces. Clinical history is often necessary to determine the etiology; however, histologic features that assist in specific diagnosis include viral inclusions suggestive of viral pneumonia, foreign body giant cells suggestive of aspiration, and poorly formed granulomas with multinucleated giant cells suggestive of hypersensitivity pneumonia. Typically, organizing pneumonia resolves with no or minimal scarring; however, clinical course and prognosis depend on the type of and severity of the underlying disease. (29,39,156-186) If, after clinical correlation and careful histologic examination for viral inclusions, foreign body giant cells, and poorly formed granulomas with associated giant cells, no etiology is determinable, the diagnosis of cryptogenic organizing pneumonia is appropriate. Cryptogenic organizing pneumonia is a clinical syndrome generally occurring in middle-aged to older women who often present with a history of flulike illness and have shortness of breath and persistent nonproductive cough. Radiologically, patchy bilateral alveolar infiltrates may occur transiently and recur in different locations. Therapeutic response to steroid therapy, and prognosis, are usually very good in patients with cryptogenic organizing pneumonia. (11)
[FIGURE 7 OMITTED]
[FIGURE 8 OMITTED]
[FIGURE 9 OMITTED]
[FIGURE 10 OMITTED]
[FIGURE 11 OMITTED]
[FIGURE 12 OMITTED]
Constrictive bronchiolitis, also termed bronchiolitis obliterans and obliterative bronchiolitis, is an obstructive small airways disease identified in a variety of disorders (Table 10). Constrictive bronchiolitis is strongly associated with chronic lung transplant rejection, for which it is a significant cause of morbidity and mortality. It may also occur as idiopathic disease, predominantly presenting as persistent cough and dyspnea, in middle-aged to older women who are never-smokers. Patients with idiopathic constrictive bronchiolitis have variable prognoses, ranging from slowly progressive disease to rapidly deteriorating disease. *** Histologically, constrictive bronchiolitis is characterized by concentric bronchiolar lumen narrowing by submucosal fibrous tissue. The lumen narrowing may range from slight and histologically subtle tomarked, with complete obliteration of the bronchiolar lumen leaving only a residual fibrous scar (Figures 13 and 14). Chronic inflammation may or may not be present in constrictive bronchiolitis, and patients with idiopathic disease often have little or no chronic inflammation within bronchiolar walls or peribronchiolar tissues. Smooth muscle hyperplasia and adventitial fibrosis may occur in membranous bronchioles. The plugs of granulation tissue found with organizing pneumonia with intraluminal polyps are not a characteristic of constrictive bronchiolitis. ([dagger])([dagger])([dagger])
TOBACCO SMOKE-ASSOCIATED BRONCHIOLITIC DISEASES
Membranous Bronchiolitis and Respiratory Bronchiolitis
Variably extensive and variably severe inflammatory and fibrotic changes caused by tobacco smoke that are found in the terminal bronchioles and respiratory bronchioles are termed, respectively, membranous bronchiolitis and respiratory bronchiolitis. (29,39,206-208) Patients are typically asymptomatic, but pulmonary function studies may show obstructive change. (29,39,206-208) Other smoking-related lung changes including chronic bronchitis, emphysema, and desquamative interstitial pneumonia may be present along with membranous bronchiolitis and respiratory bronchiolitis. Histologically, both membranous bronchiolitis and respiratory bronchiolitis contain cellular infiltrates made up predominantly of lymphocytes and histiocytes within the bronchioles and infiltrating into surrounding peribronchiolar tissue. Lying within the bronchiolar lumen and also within adjacent alveolar ducts and alveoli, there are collections of macrophages containing finely granular brown cytoplasmic pigment (Figure 10). Pigment-laden macrophages are also often found within the bronchiolar wall. Minimal to mild fibrosis may occur in the bronchial wall and adjacent alveolar septa. Metaplastic bronchiolar epithelium (lambertosis) and type II pneumocyte hyperplasia may be present. Membranous bronchiolitis may contain smooth muscle hyperplasia and adventitial fibrosis (39) (Figure 11). Patients are typically asymptomatic; however, they often show obstructive changes on pulmonary function tests. The diagnosis is often made incidentally, and prognosis in these patients is excellent with smoking cessation, with or without corticosteroid therapy. (29,39,206-208) These histologic changes are on a continuum, and when severe enough, changes of respiratory bronchiolitis are termed respiratory bronchiolitis-associated interstitial lung disease (RBILD).
Respiratory Bronchiolitis-Associated Interstitial Lung Disease
Patients with respiratory bronchiolitis histologically, who are typically heavy smokers, with generally mild nonprogressive symptoms of dyspnea and cough, and with radiologic changes of interstitial lung disease, are diagnosed as having RBILD. ([double dagger])([double dagger])([double dagger]) The differential diagnosis of respiratory bronchiolitis and RBILD is generally based on clinical and radiologic features. Some cases have been reported in nonsmokers, and similar histologic features have been seen in patients with asbestos and nonasbestos mineral dust exposure. (207,221) Chest x-ray results may be normal or may show fine reticulonodular interstitial opacities, corresponding to fibrosis involving the subpleural alveolar septa, that may be diffuse or predominate within the lung bases. High-resolution CT scan shows ground glass opacities, centrilobular nodules, and interstitial thickening with an upper lung zone predominance. ([section])([section])([section]) The histologic features of RBILD and respiratory bronchiolitis are generally indistinguishable, although some cases of RBILD may showmore pronounced changes. Histologic diagnosis of RBILD requires more than mere collections of pigmented macrophages within bronchiolar airspaces, as may be seen in healthy cigarette smokers. (29,39,207,208) More pronounced cases of RBILD merge in the continuum with cases of desquamative interstitial pneumonia (29) (Figure 12).
Pulmonary Langerhans Cell Histiocytosis
Pulmonary Langerhans cell histiocytosis commonly arises within a background of respiratory bronchiolitis and should be considered as a possible concurrent disease process in patients with respiratory bronchiolitis. (39,225) Pulmonary Langerhans cell histiocytosis has recently been reviewed. (226)
HYPERSENSITIVITY PNEUMONITIS (EXTRINSIC ALLERGIC ALVEOLITIS)
Although late-stage hypersensitivity pneumonitis can mimic usual interstitial pneumonia and nonspecific interstitial pneumonia, in earlier stage hypersensitivity pneumonitis cellular bronchiolitis is one of its characteristic histologic features, along with organizing pneumonia and poorly formed nonnecrotizing granulomas. (29,39,227) Hypersensitivity pneumonitis is often in the differential diagnosis of cellular bronchiolitis, with and without fibrotic changes. Detailed reviews of hypersensitivity pneumonitis have been recently published. (228-231)
MINERAL DUST-ASSOCIATED AND VARIOUS OTHER EXPOSURE-RELATED BRONCHIOLITIC DISEASES
Mineral Dust-Associated Bronchiolitic Diseases
Numerous mineral dust-associated airway diseases, including asbestosis, silicosis, and coal miner's pneumoconiosis, among others, may cause bronchiolitic disease. (29,39,67,232-257) The histologic changes typically consist of varying degrees of fibrosis that ultimately may obstruct and completely occlude the airway. The exact histologic pattern depends on the specific dust being inhaled and the amount of dust inhaled. Care must be taken to make a correct diagnosis, and clinical and radiologic correlation is necessary. For example, in some patients, especially heavy smokers, anthracotic pigment may be identified along alveolar ducts and respiratory bronchioles; however, there is typically less pigment deposition and less airway fibrosis than in patients with mineral dust-associated bronchiolitic diseases. ****
Exposure to Fumes and Toxins
The most serious pulmonary exposures characteristically cause overwhelming pulmonary edema, with or without diffuse alveolar damage, and frequently cause death. Lesser exposures to fumes and toxins may cause bronchiolitic disease. ([dagger]) ([dagger])([dagger])([dagger]) Patients may have cough and dyspnea, as well as other symptoms such as vomiting, dizziness, and headache. Radiographic studies may show thickened bronchioles. Acutely, histologic changes include necrotic bronchiolar mucosa with a neutrophilic infiltrate and sloughing. Pulmonary edema and changes of diffuse alveolar damage may also be present to variable degrees. The acute stage is followed by an organizing stage characterized histologically by organizing pneumonia (organizing pneumonia with intraluminal polyps). Patients who progress beyond the acute and organizing stages of disease often recover without long-term lung changes. Some patients may, however, progress chronically and show constrictive bronchiolitis. Numerous chemicals may cause bronchiolitic disease, including smoke, chlorine gas, phosgene, and hydrogen fluoride, among others. Reports have recently shown that the inhalation of volatile diacetyl as part of the popcorn manufacturing process has caused bronchiolitis, frequently constrictive bronchiolitis, in some workers. Other exposures may also cause bronchiolitis, including fiber inhalation in the nylon flocking industry. Recent reports have shown that some workers involved with flocking, in which short synthetic fibers are applied to a backing fabric, have been diagnosed with chronic bronchiolitis, often follicular bronchiolitis (Figure 15). Toxin and fume exposure may also show histologic features of organizing pneumonia with intraluminal polyps. That histologic pattern may predominate in cases of acute exposures. ([double dagger])([double dagger]) ([double dagger])
A great number of drugs cause drug-induced pulmonary toxicity. There are several histologic patterns that may occur, including diffuse alveolar hemorrhage, diffuse alveolar damage, and nonspecific interstitial pneumonia. Bronchiolitic disease, including organizing pneumonia and hypersensitivity pneumonitis, may also occur as a consequence of pulmonary drug reactions. Methotrexate is one drug commonly associated with hypersensitivity pneumonitis-associated drug-induced lung injury, although many other drugs can give a similar histologic pattern (Figure 16). Numerous drugs may cause an organizing pneumonia pattern of injury. (297-305)
OTHER BRONCHIOLITIC DISEASES
Finally, there are a few related relatively recently described bronchiolitic diseases that bear some discussion.
Airway-Centered Interstitial Fibrosis, Idiopathic Bronchiolocentric Idiopathic Pneumonia, and PeribronchiolarMetaplasia-Related Interstitial Lung Disease
Three recently described airway-centered entities, possibly representing similar manifestations or differing points of progression of the same disease or group of diseases, include airway-centered interstitial fibrosis, idiopathic bronchiolocentric idiopathic pneumonia, and peribronchiolar metaplasia-related interstitial lung disease.
Airway-centered interstitial fibrosis is the term used by Churg et al (306) in 2004 to describe the histologic features of interstitial fibrosis that is centered around bronchioles, with associated peribronchiolar fibrosis extending into surrounding lung parenchyma, increased bronchiolar smooth muscle, and metaplastic bronchiolar epithelium (lambertosis), with little interstitial inflammation. (29,306-312) Increased alveolar macrophages and honeycombing are not characteristics of airway-centered interstitial fibrosis. This uncommon diagnosis remains controversial, as these histologic features may be due to other, established, diseases such as hypersensitivity pneumonitis and RBILD. Whether airway-centered interstitial fibrosis ultimately is classified as an individual, specific form of interstitial lung disease remains to be determined. Usual interstitial pneumonia and nonspecific interstitial pneumonia are also differential diagnoses in these patients. Lung injury due to environmental exposures has been proposed as a cause of disease. Patients reportedly are middle-aged, and the majority are women. Chest x-rays generally show peribronchial and perivascular fibrosis with interstitial thickening. Patients reportedly present with chronic cough and progressive dyspnea. Treatment with bronchodilators and corticosteroids has been generally unsatisfactory. Patients have a generally poor prognosis, with a reported 40% dead of disease with follow-up periods of 1 to 10 years. Airway-centered interstitial fibrosis has features in common with idiopathic bronchiolocentric interstitial pneumonia. (29,306-312)
Idiopathic bronchiolocentric interstitial pneumonia was reported by Yousem and Dacic (313) in 2002. The authors described histologically centrilobular and bronchiolocentric fibrosis with patchy interstitial inflammation. Granulomas are not characteristic of the process. Patients reportedly were predominantly middle-aged women. Prognosis was generally guarded, with 33% of patients dead of disease and 56% alive with persistent progressive disease, with a mean follow-up period of 4 years with 9 patients. Compared with airway-centered interstitial fibrosis, idiopathic bronchiolocentric interstitial pneumonia has a more substantial interstitial inflammatory infiltrate. The diagnosis of idiopathic bronchiolocentric interstitial pneumonia is controversial, and whether these patients represent cases of hypersensitivity pneumonitis or nonspecific interstitial pneumonia remains to be determined. Differential diagnosis also includes usual interstitial pneumonia and RBILD. (29,312-314)
Fukuoka et al (315) reported 15 cases of peribronchiolar metaplasia-related interstitial lung disease. These cases differed from those reported by Churg et al and Yousem et al in that although the patients had interstitial lung disease clinically, the primary histologic finding on biopsy was peribronchiolar metaplasia. The authors designated this finding peribronchiolar metaplasia-related interstitial lung disease because of the analogy with respiratory bronchiolitis and RBILD, in which respiratory bronchiolitis is a common incidental finding in smokers and RBILD is the smoking-associated clinically significant interstitial lung disease. (315) The authors noted that although the cases reported by Churg et al and Yousem et al contained cases with peribronchiolar metaplasia, their cases did not have other features found in the cases reported by Churg et al and Yousem et al, including significant interstitial fibrosis beyond the peribronchiolar region. The authors suggested that the better prognosis identified in their cases relative to those of Churg et al and Yousem et al may be related to the absence of significant interstitial fibrosis beyond the peribronchiolar region. (315) The authors note that peribronchiolar metaplasia frequently occurs as a histologic feature in other interstitial lung diseases and that chronic hypersensitivity pneumonitis is the most important differential diagnosis in cases with these histologic features. (315)
S androgynus Ingestion
Ingestion of S androgynus, a common Malaysian vegetable also termed Sabah vegetable, was first associated with bronchiolitic disease in Taiwan and reported by Lai et al (316) and Lin et al (317) in 1996. (316-336) The plant was ingested as raw leaves or extract juice by predominantly young to middle-aged women for the perceived weight loss benefit. Patients were reported to exhibit dyspnea and cough with progressive respiratory failure developing. Some patients have died of disease. Cases have been reported in other countries, including Japan. Cause is uncertain; however, T-cell mediated immunity is thought to play a role in disease. Familial associations (mother and daughter) have been identified. Intake cessation, corticosteroids, bronchodilators, cytotoxic agents, and plasmapheresis have been attempted; however, lung transplantation has been considered to be the only effective treatment. Reports show histologic changes of segmental necrosis of small bronchi with relative sparing of large bronchi, most bronchioles, and alveoli. As well, bronchial arteries within walls of large bronchi show fibromuscular sclerosis and obliteration. In some cases, constrictive bronchiolitis and organizing pneumonia (organizing pneumonia with intraluminal polyps) has been reported, possibly representing indirect histologic changes. (316-332,336)
[FIGURE 13 OMITTED]
[FIGURE 14 OMITTED]
[FIGURE 15 OMITTED]
[FIGURE 16 OMITTED]
Bronchiolitis Interstitial Pneumonitis
Bronchiolitis interstitial pneumonitis was described recently by Mark and Ruangchira-urai. (337) Histologically, bronchiolitis interstitial pneumonitis reportedly shows regional and occasionally widespread organizing pneumonia with associated alveolar inflammation and alveolar fibrosis in most cases. Many cases contained bronchiolar scarring and mucus plugging, and some cases showed purulent bronchiolitis. Differential diagnosis includes usual interstitial pneumonia, nonspecific interstitial pneumonia, organizing pneumonia, and constrictive bronchiolitis, as well as the also recently described diagnoses of airway-centered interstitial pneumonia and idiopathic bronchiolocentric interstitial pneumonia. Whether bronchiolitis interstitial pneumonitis is ultimately classified as an individual, specific form of interstitial lung disease remains to be determined, and further studies of cases with these histologic features will help better characterize these patients.
Small airways diseases include a wide variety of diseases of which the pathologist must consider. Although uncommon conditions such as diffuse idiopathic neuroendocrine cell hyperplasia and diffuse panbronchiolitis have histologic features that allow for relatively specific diagnoses, and although some conditions such as mineral dust-associated small airways disease, RBILD, granulomatous bronchiolitis, eosinophilic bronchiolitis, and fol licular bronchiolitis have histologic features that may be diagnostic in the appropriate clinical and radiologic setting, most cellular and fibrotic changes found in small airways disease are nonspecific. These nonspecific small airways findings are found in a variety of both primary small airways diseases and diseases that affect the small airways secondarily, such as hypersensitivity pneumonitis, asthma, chronic obstructive pulmonary disease, and Wegener granulomatosis. Diseases and conditions that are not considered primarily pulmonary, such as collagen vascular diseases, bone marrow transplantation, and inflammatory bowel disease, must also be considered in patients with significant histologic changes in the small airways. More recently described entities such as airway-centered interstitial fibrosis and bronchiolocentric interstitial pneumonia must be further studied to determine whether these cases represent separate, independent diagnostic entities or whether they represent uncommon presentations of recognized entities such as hypersensitivity pneumonitis.
(1.) Bake B. Is maximum mid-expiratory flow rate sensitive to small airways obstruction? Eur J Respir Dis. 1981;62:150-151.
(2.) Chen CZ, Lin CC, Lee CH, Chang HY, Hsiue TR. Small airways obstruction syndrome in clinical practice. Respirology. 2009;14:393-398.
(3.) Cohen J, Postma DS, Vink-Klooster K, et al. FVC to slow inspiratory vital capacity ratio: a potential marker for small airways obstruction. Chest. 2007;132: 1198-1203.
(4.) Kelman GR. Assessment of airway obstruction with particular reference to the small airways. J Soc Occup Med. 1980;30:157-163.
(5.) Obtulowicz K, Laczkowska T, Kolarzyk E, Hudzik A. Obstruction of the small airways in the spirometric diagnosis of occupational bronchial asthma. J Investig Allergol Clin Immunol. 1998;8:300-303.
(6.) Stanescu D. Small airways obstruction syndrome. Chest. 1999;116:231-233.
(7.) Thurlbeck WM. The pathology of small airways in chronic airflow limitation. Eur J Respir Dis Suppl. 1982;121:9-18.
(8.) Wright GD, Roberts SD, Finch MB, Martin B. Long-term follow up of small airways obstruction in patients with rheumatoid arthritis. Ann Rheum Dis. 1998; 57:258.
(9.) Schlesinger C, Meyer CA, Veeraraghavan S, Koss MN. Constrictive (obliterative) bronchiolitis: diagnosis, etiology, and a critical review of the literature. Ann Diagn Pathol. 1998;2:321-334.
(10.) Vilchez RA, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection--myth or reality? Am J Transplant. 2003;3:245-249.
(11.) Valentine VG, Gupta MR, Walker JE Jr, et al. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2009;28:163-169.
(12.) Izumi T, Kitaichi M, Nishimura K, Nagai S. Bronchiolitis obliterans organizing pneumonia: clinical features and differential diagnosis. Chest. 1992; 102:715-719.
(13.) Kitaichi M. Differential diagnosis of bronchiolitis obliterans organizing pneumonia. Chest. 1992;102:44S-49S.
(14.) Nakanishi M, Demura Y, Mizuno S, et al. Changes in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after smoking cessation. Eur Respir J. 2007;29:453-461.
(15.) Hansell DM. HRCT of obliterative bronchiolitis and other small airways diseases. Semin Roentgenol. 2001;36:51-65.
(16.) Hansell DM, Rubens MB, Padley SP, Wells AU. Obliterative bronchiolitis: individual CT signs of small airways disease and functional correlation. Radiology. 1997;203:721-726.
(17.) Hwang JH, Kim TS, Lee KS, et al. Bronchiolitis in adults: pathology and imaging. J Comput Assist Tomogr. 1997;21:913-919.
(18.) Muller NL, Miller RR. Diseases of the bronchioles: CT and histopathologic findings. Radiology. 1995;196:3-12.
(19.) Davies CW, Tasker AD, Padley SP, Davies RJ, Gleeson FV. Air trapping in sarcoidosis on computed tomography: correlation with lung function. Clin Radiol. 2000;55:217-221.
(20.) Stern EJ, Frank MS. Small-airway diseases of the lungs: findings at expiratory CT. AJR Am J Roentgenol. 1994;163:37-41.
(21.) Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med. 1968;278:1355-1360.
(22.) Yousem SA. Small airways disease. Pathol Annu. 1991;26(pt 2):109-143.
(23.) Myers JL, Colby TV. Pathologic manifestations of bronchiolitis, constrictive bronchiolitis, cryptogenic organizing pneumonia, and diffuse panbronchiolitis. Clin Chest Med. 1993;14:611-622.
(24.) Colby TV. Bronchiolitis. Pathologic considerations. Am J Clin Pathol. 1998;109:101-109.
(25.) Visscher DW, Myers JL. Bronchiolitis: the pathologist's perspective. Proc Am Thorac Soc. 2006;3:41-47.
(26.) Tomashefski JF CP, Farver CF, Fraire AE, ed. Dail and Hammar's Pulmonary Pathology. 3rd ed. New York, NY: Springer; 2008.
(27.) Katzenstein A-LA. Miscellaneous II: nonspecific inflammatory and destructive diseases. In: Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease. 4th ed. Philadelphia, PA: Elsevier; 2006:445-476.
(28.) Wang C-W, Muhm JR, Colby TV, Leslie KO. Small airway lesions. In: Cagle PT, Allen TC, Beasley MB, eds. Diagnostic Pulmonary Pathology. 2nd ed. New York, NY: Informa; 2008:229-247.
(29.) Cagle PT. Color Atlas and Text of Pulmonary Pathology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
(30.) Poletti V, Zompatori M, Cancellieri A. Clinical spectrum of adult chronic bronchiolitis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:183-196.
(31.) Worthy SA, Muller NL. Small airway diseases. Radiol Clin North Am. 1998;36:163-173.
(32.) James A, Carroll N. Transbronchial biopsy as a tool to evaluate small-airways disease in asthma: cons. Eur Respir J. 2002;20:249-251.
(33.) Vikgren J, Bake B, Ekberg-Jansson A, Larsson S, Tylen U. Value of air trapping in detection of small airways disease in smokers. Acta Radiol. 2003;44: 517-524.
(34.) Sturton G, Persson C, Barnes PJ. Small airways: an important but neglected target in the treatment of obstructive airway diseases. Trends Pharmacol Sci. 2008;29:340-345.
(35.) Lynch DA. Imaging of small airways disease and chronic obstructive pulmonary disease. Clin Chest Med. 2008;29:165-179, vii.
(36.) Wang CW, Muhm JR, Colby TV, Leslie KO. Small airway lesions. In: Cagle PT, Allen TC, Beasley MB, eds. Diagnostic Pulmonary Pathology. 2nd ed. New York, NY: Informa; 2008:229-249.
(37.) Barbareschi M, Leslie K. Pathology of the large and small airways. In: Leslie KO, Wick MR, eds. Practical Pulmonary Pathology. Philadelphia, PA: Churchill Livingstone; 2005:259-302.
(38.) Ryu JH, Colby TV, Hartman TE, Vassallo R. Smoking-related interstitial lung diseases: a concise review. Eur Respir J. 2001;17:122-132.
(39.) Cagle PT, Allen TC, Beasley MB, eds. Diagnostic Pulmonary Pathology. 2nd ed. New York, NY: Informa; 2008.
(40.) Stanescu D, Veriter C. A normal FEV1/VC ratio does not exclude airway obstruction. Respiration. 2004;71:348-352.
(41.) Colby TV, Yousem SA. Pulmonary histology for the surgical pathologist. Am J Surg Pathol. 1988;12:223-239.
(42.) Popper HH. Bronchiolitis, an update. Virchows Arch. 2000;437:471-481.
(43.) Penn CC, Liu C. Bronchiolitis following infection in adults and children. Clin Chest Med. 1993;14:645-654.
(44.) Andersen P. Pathogenesis of lower respiratory tract infections due to chlamydia, mycoplasma, legionella and viruses. Thorax. 1998;53:302-307.
(45.) Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB. Respiratory syncytial virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am J Respir Crit Care Med. 1999;159:1918- 1924.
(46.) Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917-1928.
(47.) Panitch HB. Bronchiolitis in infants. Curr Opin Pediatr. 2001;13:256-260.
(48.) Steiner RW. Treating acute bronchiolitis associated with RSV. Am Fam Physician. 2004;69:325-330.
(49.) Fjaerli HO, Farstad T, Rod G, Ufert GK, Gulbrandsen P, Nakstad B. Acute bronchiolitis in infancy as risk factor for wheezing and reduced pulmonary function by seven years in Akershus County, Norway. BMC Pediatr. 2005;5:31.
(50.) Perrotta C, Ortiz Z, Roque M. Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. Cochrane Database Syst Rev. 2005:CD004873.
(51.) Wong JY, Rutman A, O'Callaghan C. Recovery of the ciliated epithelium following acute bronchiolitis in infancy. Thorax. 2005;60:582-587.
(52.) Bush A, Thomson AH. Acute bronchiolitis. BMJ. 2007;335:1037-1041.
(53.) Calogero C, Sly PD. Acute viral bronchiolitis: to treat or not to treat-that is the question. J Pediatr. 2007;151:235-237.
(54.) Schuh S, Lalani A, Allen U, et al. Evaluation of the utility of radiography in acute bronchiolitis. J Pediatr. 2007;150:429-433.
(55.) Thiessen PN. Acute bronchiolitis: there may be a treatment. BMJ. 2007; 335:1109.
(56.) Barben J, Kuehni CE, Trachsel D, Hammer J. Management of acute bronchiolitis: can evidence based guidelines alter clinical practice? Thorax. 2008;63:1103-1109.
(57.) Marguet C, Bocquel N, Benichou J, et al. Neutrophil but not eosinophil inflammation is related to the severity of a first acute epidemic bronchiolitis in young infants. Pediatr Allergy Immunol. 2008;19:157-165.
(58.) Smith J, Salinas R. Do systemic corticosteroids improve acute outcomes in infants with RSV bronchiolitis? J Okla State Med Assoc. 2008;101:14.
(59.) Wright M, Mullett CJ, Piedimonte G. Pharmacological management of acute bronchiolitis. Ther Clin Risk Manag. 2008;4:895-903.
(60.) Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2008:CD006458.
(61.) Everard ML. Acute bronchiolitis and croup. Pediatr Clin North Am. 2009; 56:119-133.
(62.) Yong JH, Schuh S, Rashidi R, et al. A cost effectiveness analysis of omitting radiography in diagnosis of acute bronchiolitis. Pediatr Pulmonol. 2009;44:122-127.
(63.) Franquet T, Stern EJ. Bronchiolar inflammatory diseases: high-resolution CT findings with histologic correlation. Eur Radiol. 1999;9:1290-1303.
(64.) Stempel HE, Martin ET, Kuypers J, Englund JA, Zerr DM. Multiple viral respiratory pathogens in children with bronchiolitis. Acta Paediatr. 2009;98:123-126.
(65.) Forton JT, Rowlands K, Hanchard N, Herbert M, Kwiatkowski DP, Hull J. Genetic association study for RSV bronchiolitis in infancy at the 5q31 cytokine cluster. Thorax. 2009;64(4):345-352.
(66.) Kim CK, Kim SW, Kim JS, et al. Bronchiolitis obliterans in the 1990s in Korea and the United States. Chest. 2001;120:1101-1106.
(67.) Wright JL, Cagle P, Churg A, Colby TV, Myers J. Diseases of the small airways. Am Rev Respir Dis. 1992;146:240-262.
(68.) King TE Jr. Overview of bronchiolitis. Clin Chest Med. 1993;14:607-610.
(69.) McNamara PS, Smyth RL. The pathogenesis of respiratory syncytial virus disease in childhood. Br Med Bull. 2002;61:13-28.
(70.) Johnson BA, Iacono AT, Zeevi A, McCurry KR, Duncan SR. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med. 2003;167:1271-1278.
(71.) Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med. 2003;168:1277-1292.
(72.) Ryu JH. Classification and approach to bronchiolar diseases. Curr Opin Pulm Med. 2006;12:145-151.
(73.) Bajaj L, Turner CG, Bothner J. A randomized trial of home oxygen therapy from the emergency department for acute bronchiolitis. Pediatrics. 2006;117: 633-640.
(74.) Cambonie G, Milesi C, Fournier-Favre S, et al. Clinical effects of heliox administration for acute bronchiolitis in young infants. Chest. 2006;129:676-682.
(75.) Joseph L, Goldberg S, Picard E. A randomized trial of home oxygen therapy from the emergency department for acute bronchiolitis. Pediatrics. 2006; 118:1319-1320; author reply 1320-1321.
(76.) Martinon-Torres F, Rodriguez-Nunez A, Martinon-Sanchez JM. Nasal continuous positive airway pressure with heliox in infants with acute bronchiolitis. Respir Med. 2006;100:1458-1462.
(77.) Amirav I, Luder AS, Kruger N, et al. A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis. Pediatrics. 2008;122: e1249-e1255.
(78.) Tie SW, Hall GL, Peter S, et al. Home oxygen for children with acute bronchiolitis. Arch Dis Child. 2009;94(8):641-643.
(79.) Unger S, Cunningham S. Effect of oxygen supplementation on length of stay for infants hospitalized with acute viral bronchiolitis. Pediatrics. 2008;121: 470-475.
(80.) Romero S, Barroso E, Gil J, Aranda I, Alonso S, Garcia-Pachon E. Follicular bronchiolitis: clinical and pathologic findings in six patients. Lung. 2003;181: 309-319.
(81.) Exley CM, Suvarna SK, Matthews S. Follicular bronchiolitis as a presentation of HIV. Clin Radiol. 2006;61:710-713.
(82.) Roddy E, Summers G, Chaudry Z, Bateman R. Follicular bronchiolitis, an unusual cause of haemoptysis in giant cell arteritis. Clin Rheumatol. 2006;25: 433-435.
(83.) Aerni MR, Vassallo R, Myers JL, Lindell RM, Ryu JH. Follicular bronchiolitis in surgical lung biopsies: clinical implications in 12 patients. Respir Med. 2008;102:307-312.
(84.) Vos R, Vanaudenaerde BM, De Vleeschauwer SI, et al. Follicular bronchiolitis: a rare cause of bronchiolitis obliterans syndrome after lung transplantation: a case report. Am J Transplant. 2009;9(3):644-650.
(85.) Yousem SA, Colby TV, Carrington CB. Follicular bronchitis/bronchiolitis. Hum Pathol. 1985;16:700-706.
(86.) Fortoul TI, Cano-Valle F, Oliva E, Barrios R. Follicular bronchiolitis in association with connective tissue diseases. Lung. 1985;163:305-314.
(87.) Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS. Surgical pathology of the lung in Wegener's granulomatosis: review of 87 open lung biopsies from 67 patients. Am J Surg Pathol. 1991;15:315-333.
(88.) Kinoshita M, Higashi T, Tanaka C, Tokunaga N, Ichikawa Y, Oizumi K. Follicular bronchiolitis associated with rheumatoid arthritis. Intern Med. 1992; 31:674-677.
(89.) Kinane BT, Mansell AL, Zwerdling RG, Lapey A, Shannon DC. Follicular bronchitis in the pediatric population. Chest. 1993;104:1183-1186.
(90.) Sato A, Hayakawa H, Uchiyama H, Chida K. Cellular distribution of bronchus-associated lymphoid tissue in rheumatoid arthritis. Am J Respir Crit Care Med. 1996;154:1903-1907.
(91.) Theron S, Goussard P. Follicular bronchiolitis in an HIV-positive child. Pediatr Radiol. 2008;38:1031.
(92.) Uzuner N, Babayigit A, Olmez D, et al. Follicular bronchiolitis associated with lung abscess in an eight-year-old girl. Turk J Pediatr. 2007;49:203-205.
(93.) Masuda T, Ishikawa Y, Akasaka Y, et al. Follicular bronchiolitis (FBB) associated with Legionella pneumophila infection. Pediatr Pathol Mol Med. 2002;21:517-524.
(94.) Howling SJ, Hansell DM, Wells AU, Nicholson AG, Flint JD, Muller NL. Follicular bronchiolitis: thin-section CT and histologic findings. Radiology. 1999; 212:637-642.
(95.) Wechsler ME. Pulmonary eosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:477-492.
(96.) Takayanagi N, Kanazawa M, Kawabata Y, Colby TV. Chronic bronchiolitis with associated eosinophilic lung disease (eosinophilic bronchiolitis). Respiration. 2001;68:319-322.
(97.) Olopade CO, Crotty TB, Douglas WW, Colby TV, Sur S. Chronic eosinophilic pneumonia and idiopathic bronchiolitis obliterans organizing pneumonia: comparison of eosinophil number and degranulation by immunofluorescence staining for eosinophil-derived major basic protein. Mayo Clin Proc. 1995;70:137-142.
(98.) Cooney TP. Interrelationship of chronic eosinophilic pneumonia, bronchiolitis obliterans, and rheumatoid disease: a hypothesis. J Clin Pathol. 1981;34: 129-137.
(99.) Bosken CH, Myers JL, Greenberger PA, Katzenstein AL. Pathologic features of allergic bronchopulmonary aspergillosis. Am J Surg Pathol. 1988;12:216-222.
(100.) Randhawa P, Hoagland MH, Yousem SA. Diffuse panbronchiolitis in North America: report of three cases and review of the literature. Am J Surg Pathol. 1991;15:43-47.
(101.) Kim YW, Han SK, Shim YS, et al. The first report of diffuse panbronchiolitis in Korea: five case reports. Intern Med. 1992;31:695-701.
(102.) Poletti V, Patelli M, Poletti G, Bertanti T, Spiga L. Diffuse panbronchiolitis observed in an Italian male. Sarcoidosis. 1992;9:67-69.
(103.) Homer RJ, Khoo L, Smith GJ. Diffuse panbronchiolitis in a Hispanic man with travel history to Japan. Chest. 1995;107:1176-1178.
(104.) Brugiere O, Milleron B, Antoine M, Carette MF, Philippe C, Mayaud C. Diffuse panbronchiolitis in an Asian immigrant. Thorax. 1996;51:1065-1067.
(105.) Fitzgerald JE, King TE Jr, Lynch DA, Tuder RM, Schwarz MI. Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med. 1996;154:497-503.
(106.) Zainudin BM, Roslina AM, Fadilah SA, Samad SA, Sufarlan AW, Isa MR. A report of the first three cases of diffuse panbronchiolitis in Malaysia. Med J Malaysia. 1996;51:136-140.
(107.) Fisher MS Jr, Rush WL, Rosado-de-Christenson ML, et al. Diffuse panbronchiolitis: histologic diagnosis in unsuspected cases involving North American residents of Asian descent. Arch Pathol Lab Med. 1998;122:156-160.
(108.) Ng P, Dwyer R, Despas P. Diffuse panbronchiolitis: case report and review of the literature. Australas Radiol. 1998;42:146-150.
(109.) Chantarotorn S, Palwatwichai A, Vattanathum A, Tantamacharik D. Diffuse panbronchiolitis, the first case reports in Thailand. J Med Assoc Thai. 1999;82:833-838.
(110.) Claxton S, Markos J. A case of diffuse panbronchiolitis. Aust N Z J Med. 2000;30:99-100.
(111.) Gulhan M, Erturk A, Kurt B, et al. Diffuse panbronchiolitis observed in a white man in Turkey. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:292-296.
(112.) Poh SC, Wang YT, Wang WY. Diffuse panbronchiolitis--a case report. Singapore Med J. 2001;42:271-274.
(113.) Keicho N, Kudoh S. Diffuse panbronchiolitis: role of macrolides in therapy. Am J Respir Med. 2002;1:119-131.
(114.) Krishnan P, Thachil R, Gillego V. Diffuse panbronchiolitis: a treatable sinobronchial disease in need of recognition in the United States. Chest. 2002; 121:659-661.
(115.) Souza R, Kairalla RA, Santos Ud Ude P, Takagaki TY, Capelozzi VL, Carvalho CR. Diffuse panbronchiolitis: an underdiagnosed disease?: study of 4 cases in Brazil. Rev Hosp Clin Fac Med Sao Paulo. 2002;57:167-174.
(116.) Kudoh S, Keicho N. Diffuse panbronchiolitis. Semin Respir Crit Care Med. 2003;24:607-618.
(117.) Sandrini A, Balter MS, Chapman KR. Diffuse panbronchiolitis in a Caucasian man in Canada. Can Respir J. 2003;10:449-451.
(118.) Poletti V, Chilosi M, Casoni G, Colby TV. Diffuse panbronchiolitis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:94-104.
(119.) Xie GS, Li LY, Liu HR, Zhang WH, Zhu YJ. Diffuse panbronchiolitis with histopathological confirmation among Chinese. Chin Med J (Engl). 2004;117: 1299-1303.
(120.) Chen Y, Kang J, Li S. Diffuse panbronchiolitis in China. Respirology. 2005;10:70-75.
(121.) Azuma A, Kudoh S. Diffuse panbronchiolitis in East Asia. Respirology. 2006;11:249-261.
(122.) Poletti V, Casoni G, Chilosi M, Zompatori M. Diffuse panbronchiolitis. Eur Respir J. 2006;28:862-871.
(123.) Ding K, Liu MB, Wu JL, et al. Diffuse panbronchiolitis in China: analysis of 45 cases. Chin Med J (Engl). 2007;120:2046-2048.
(124.) Lum D, Wong C, Anderson G, Taylor G. Test and teach: number fifty-three: a rare lung disease in an Indian man: diagnosis: diffuse panbronchiolitis. Pathology. 2007;39:594-597.
(125.) McGrath EE, McLaughlin AM, Fitzgerald MX. Diffuse panbronchiolitis: East meets West. Eur Respir J. 2007;29:817-818.
(126.) Adams NP, Congelton J. Diffuse panbronchiolitis. Eur Respir J. 2008;32: 237-238.
(127.) She J, Sun Q, Fan L, Qin H, Bai C, Shen C. Association of HLA genes with diffuse panbronchiolitis in Chinese patients. Respir Physiol Neurobiol. 2007;157: 366-373.
(128.) Keicho N, Ohashi J, Tamiya G, et al. Fine localization of a major disease-susceptibility locus for diffuse panbronchiolitis. Am J Hum Genet. 2000;66:501-507.
(129.) Sugiyama Y, Kudoh S, Maeda H, Suzaki H, Takaku F. Analysis of HLA antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis. 1990;141: 1459-1462.
(130.) Keicho N, Tokunaga K, Nakata K, et al. Contribution of HLA genes to genetic predisposition in diffuse panbronchiolitis. Am J Respir Crit Care Med. 1998;158:846-850.
(131.) Matsuno O, Watanabe K, Kataoka H, Miyazaki E, Kumamoto T. A case of diffuse panbronchiolitis (DPB) in a patient positive for HTLV-1. Scand J Infect Dis. 2004;36:687-689.
(132.) Aslan AT, Ozcelik U, Talim B, et al. Childhood diffuse panbronchiolitis: a case report. Pediatr Pulmonol. 2005;40:354-357.
(133.) Homma S, Sakamoto S, Kawabata M, et al. Comparative clinicopathology of obliterative bronchiolitis and diffuse panbronchiolitis. Respiration. 2006; 73:481-487.
(134.) Sugiyama Y. Diffuse panbronchiolitis. Clin Chest Med. 1993;14:765-772.
(135.) Yamanaka A, Saiki S, Tamura S, Saito K. Problems in chronic obstructive bronchial diseases, with special reference to diffuse panbronchiolitis [in Japanese]. Naika. 1969;23:442-451.
(136.) Kadota J, Mukae H, Tomono K, Kohno S, Nasu M. Efficacy of long-term macrolide antibiotic therapy in patients with diffuse panbronchiolitis: comparison between HLA-B54-positive and -negative cases. Int J Antimicrob Agents. 2004;24:550-554.
(137.) Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother. 2004;54:21-28.
(138.) Kadota J, Mukae H, Mizunoe S, et al. Long-term macrolide antibiotic therapy in the treatment of chronic small airway disease clinically mimicking diffuse panbronchiolitis. Intern Med. 2005;44:200-206.
(139.) Heffelfinger SC, Weilbaecher DG, Lawrence EC, Johnson EH, Greenberg SD. Xanthomatous bronchiolitis obliterans with cholesterol pneumonia. Arch Pathol Lab Med. 1988;112:650-653.
(140.) Hayakawa H, Sato A, Imokawa S, et al. Diffuse panbronchiolitis and rheumatoid arthritis-associated bronchiolar disease: similarities and differences. Intern Med. 1998;37:504-508.
(141.) Park J, Banno S, Sugiura Y, et al. Microscopic polyangiitis associated with diffuse panbronchiolitis. Intern Med. 2004;43:331-335.
(142.) Poletti V, Chilosi M, Trisolini R, et al. Idiopathic bronchiolitis mimicking diffuse panbronchiolitis. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:62-68.
(143.) Yousem SA. The histological spectrum of chronic necrotizing forms of pulmonary aspergillosis. Hum Pathol. 1997;28:650-656.
(144.) Vandenplas O, Casel S, Delos M, Trigaux JP, Melange M, Marchand E. Granulomatous bronchiolitis associated with Crohn's disease. Am J Respir Crit Care Med. 1998;158:1676-1679.
(145.) Tabarsi P, Mirsaeidi M, Karimi S, et al. Lymphocytic bronchiolitis as presenting disorder in an undiagnosed adult patient with chronic granulomatous disease. Iran J Allergy Asthma Immunol. 2007;6:219-221.
(146.) Morresi-Hauf A, Neher A, Wockel W, Kammler-Baumann H. Granulomatous bronchiolitis due to aspiration of Lycopodium spores by fire-breathing [in German]. Pneumologie. 2009;63(2):67-71.
(147.) Mark EJ, Flieder DB, Matsubara O. Treated Wegener's granulomatosis: distinctive pathological findings in the lungs of 20 patients and what they tell us about the natural history of the disease. Hum Pathol. 1997;28:450-458.
(148.) Lahdensuo A, Mattila J, Vilppula A. Bronchiolitis in rheumatoid arthritis. Chest. 1984;85:705-708.
(149.) Kambouchner M, Basset F, Marchal J, Uhl JF, Hance AJ, Soler P. Three-dimensional characterization of pathologic lesions in pulmonary Langerhans cell histiocytosis. Am J Respir Crit Care Med. 2002;166:1483-1490.
(150.) Grimes MM, Cole TJ, Fowler AA III. Obstructive granulomatous bronchiolitis due to Mycobacterium avium complex in an immunocompetent man. Respiration. 2001;68:411-415.
(151.) Freeman HJ, Davis JE, Prest ME, Lawson EJ. Granulomatous bronchiolitis with necrobiotic pulmonary nodules in Crohn's disease. Can J Gastroenterol. 2004;18:687-690.
(152.) Duarte IG, Gal AA, Mansour KA, Lee RB, Miller JI. Pathologic findings in lung volume reduction surgery. Chest. 1998;113:660-664.
(153.) Chetty A. Pathology of allergic bronchopulmonary aspergillosis. Front Biosci. 2003;8:e110-e114.
(154.) Casey MB, Tazelaar HD, Myers JL, et al. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol. 2003;27:213-219.
(155.) Agarwal R, Kumar V, Jindal SK. Obstructive granulomatous bronchiolitis obliterans due to Mycobacterium tuberculosis. Monaldi Arch Chest Dis. 2005;63: 108-110.
(156.) Turton CW, Williams G, Green M. Cryptogenic obliterative bronchiolitis in adults. Thorax. 1981;36:805-810.
(157.) Davison AG, Heard BE, McAllister WA, Turner-Warwick ME. Cryptogenic organizing pneumonitis. Q J Med. 1983;52:382-394.
(158.) Epler GR, Colby TV, McLoud TC, Carrington CB, Gaensler EA. Bronchiolitis obliterans organizing pneumonia. N Engl J Med. 1985;312:152-158.
(159.) Chandler PW, Shin MS, Friedman SE, Myers JL, Katzenstein AL. Radiographic manifestations of bronchiolitis obliterans with organizing pneumonia vs usual interstitial pneumonia. AJR Am J Roentgenol. 1986;147:899-906.
(160.) Corrin B. Bronchiolitis obliterans organizing pneumonia: a British view. Chest. 1992;102:7S.
(161.) King TE Jr, Mortenson RL. Cryptogenic organizing pneumonitis: the North American experience. Chest. 1992;102:8S-13S.
(162.) Uner AH, Rozum-Slota B, Katzenstein AL. Bronchiolitis obliterans-organizing pneumonia (BOOP)-like variant of Wegener's granulomatosis: a clinicopathologic study of 16 cases. Am J Surg Pathol. 1996;20:794-801.
(163.) Yousem SA, Lohr RH, Colby TV. Idiopathic bronchiolitis obliterans organizing pneumonia/cryptogenic organizing pneumonia with unfavorable outcome: pathologic predictors. Mod Pathol. 1997;10:864-871.
(164.) Popper HH. Bronchiolitis obliterans: organizing pneumonia. Verh Dtsch Ges Pathol. 2002;86:101-106.
(165.) Taylor JG, Bolster MB. Bronchiolitis obliterans with organizing pneumonia associated with scleroderma and scleroderma spectrum diseases. J Clin Rheumatol. 2003;9:239-245.
(166.) Cordier JF. Cryptogenic organizing pneumonia. Clin Chest Med. 2004; 25:727-738, vi-vii.
(167.) Epler GR. Drug-induced bronchiolitis obliterans organizing pneumonia. Clin Chest Med. 2004;25:89-94.
(168.) Kalambokis G, Stefanou D, Arkoumani E, Tsianos E. Bronchiolitis obliterans organizing pneumonia following chlorambucil treatment for chronic lymphocytic leukemia. Eur J Haematol. 2004;73:139-142.
(169.) Kohli-Seth R, Killu C, Amolat MJ, et al. Bronchiolitis obliterans organizing pneumonia after orthotopic liver transplantation. Liver Transpl. 2004;10:456-459.
(170.) Greenberg-Wolff I, Konen E, Ben Dov I, Simansky D, Perelman M, Rozenman J. Cryptogenic organizing pneumonia: variety of radiologic findings. Isr Med Assoc J. 2005;7:568-570.
(171.) Macartney C, Burke E, Elborn S, et al. Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim. Leuk Lymphoma. 2005;46:1523-1526.
(172.) Oymak FS, Demirbas HM, Mavili E, et al. Bronchiolitis obliterans organizing pneumonia: clinical and roentgenological features in 26 cases. Respiration. 2005;72:254-262.
(173.) Cornelissen R, Senan S, Antonisse IE, et al. Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma. Radiat Oncol. 2007;2:2.
(174.) Jinta M, Ohashi K, Ohta T, et al. Clinical features of allogeneic hematopoietic stem cell transplantation-associated organizing pneumonia. Bone Marrow Transplant. 2007;40:465-472.
(175.) Maldonado F, Daniels CE, Hoffman EA, Yi ES, Ryu JH. Focal organizing pneumonia on surgical lung biopsy: causes, clinicoradiologic features, and outcomes. Chest. 2007;132:1579-1583.
(176.) White KA, Ruth-Sahd LA. Bronchiolitis obliterans organizing pneumonia. Crit Care Nurse. 2007;27:53-66; quiz 67.
(177.) Cavallasca JA, Caubet M, Helling CA, Tate GA. Cryptogenic organizing pneumonia (COP), as presentation of rheumatoid arthritis. Rheumatol Int. 2008; 29:99-101.
(178.) Crespi C, Gualandi S, Piscaglia F, Bolondi L. Onset of bronchiolitis obliterans organizing pneumonia in a liver transplant recipient under peginterferon and ribavirin treatment. Intern Emerg Med. 2008;3:77-80.
(179.) Drakopanagiotakis F, Polychronopoulos V, Judson MA. Organizing pneumonia. Am J Med Sci. 2008;335:34-39.
(180.) Ioannou S, Toya SP, Tomos P, Tzelepis GE. Cryptogenic organizing pneumonia associated with primary Sjogren's syndrome. Rheumatol Int. 2008; 28:1053-1055.
(181.) Liote H. Organizing pneumonia associated with rituximab: challenges raised by establishing causality. Joint Bone Spine. 2008;75:260-262.
(182.) Mori S, Cho I, Koga Y, Sugimoto M. A simultaneous onset of organizing pneumonia and rheumatoid arthritis, along with a review of the literature. Mod Rheumatol. 2008;18:60-66.
(183.) Ogo E, Komaki R, Fujimoto K, et al. A survey of radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy in Japan. Int J Radiat Oncol Biol Phys. 2008;71:123-131.
(184.) Ko KH, Hsu HH, Kao WY, Chang CF, Cheng MF, Huang GS. An unusual radiologic pattern of cryptogenic organizing pneumonia: diffuse pulmonary nodules in a leukemia patient. Korean J Radiol. 2009;10:93-96.
(185.) Okada F, Ando Y, Honda K, Tanoue S, Matsumoto S, Mori H. Comparison of pulmonary CT findings and serum KL-6 levels in patients with cryptogenic organizing pneumonia. Br J Radiol. 2009;82:212-218.
(186.) Cagle PT, Allen TC, Kerr KM. Transbronchial and Endobronchial Biopsies. Philadelphia, PA: Lippincott Williams & Wilkins; 2009.
(187.) Cordier JF. Bronchiolitis obliterans organizing pneumonia. Semin Respir Crit Care Med. 2000;21:135-146.
(188.) Cordier JF. Organizing pneumonia: cryptogenic and disease associated. Semin Respir Crit Care Med. 2003;24:595-606.
(189.) Cagle PT, Truong LD, Holland VA, Lawrence EC, Noon GP, Greenberg SD. Lung biopsy evaluation of acute rejection versus opportunistic infection in lung transplant patients. Transplantation. 1989;47:713-715.
(190.) Kraft M, Mortenson RL, Colby TV, Newman L, Waldron JA Jr, King TE Jr. Cryptogenic constrictive bronchiolitis: a clinicopathologic study. Am Rev Respir Dis. 1993;148:1093-1101.
(191.) Paradis I, Yousem S, Griffith B. Airway obstruction and bronchiolitis obliterans after lung transplantation. Clin Chest Med. 1993;14:751-763.
(192.) Cagle PT, Brown RW, Frost A, Kellar C, Yousem SA. Diagnosis of chronic lung transplant rejection by transbronchial biopsy. Mod Pathol. 1995;8:137-142.
(193.) Frost AE, Keller CA, Noon GP, Short HD, Cagle PT. Outcome of the native lung after single lung transplant: Multiorgan Transplant Group. Chest. 1995;107:981-984.
(194.) Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant. 1996;15:1-15.
(195.) Brown MJ, English J, Muller NL. Bronchiolitis obliterans due to neuroendocrine hyperplasia: high-resolution CT--pathologic correlation. AJR Am J Roentgenol. 1997;168:1561-1562.
(196.) Kreiss K. Flavoring-related bronchiolitis obliterans. Curr Opin Allergy Clin Immunol. 2007;7:162-167.
(197.) Kanwal R. Bronchiolitis obliterans in workers exposed to flavoring chemicals. Curr Opin Pulm Med. 2008;14:141-146.
(198.) Sobande PO, Acton JD, Amin RS, Weiland J. Obliterative bronchiolitis in a 13-year-old pre-transplant cystic fibrosis patient. J Cyst Fibros. 2008;7:92-94.
(199.) Yilmaz O, Savas R, Sogut A, Ozkol M, Yuksel H. Effectiveness of magnetic resonance angiography in the evaluation of lung perfusion in constrictive bronchiolitis obliterans. Respirology. 2009;14(2):295-298.
(200.) Devouassoux G, Cottin V, Liote H, et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J. 2009;33(5):1053-1061.
(201.) Galbraith D, Weill D. Popcorn lung and bronchiolitis obliterans: a critical appraisal. Int Arch Occup Environ Health. 2009;82:407-416.
(202.) Hayes D Jr, Ballard H. Saber-sheath trachea in a patient with bronchiolitis obliterans syndrome after lung transplantation. Chron Respir Dis. 2009;6:49-52.
(203.) Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology. 2009; 14:129-133.
(204.) Ezri T, Kunichezky S, Eliraz A, Soroker D, Halperin D, Schattner A. Bronchiolitis obliterans--current concepts. Q J Med. 1994;87:1-10.
(205.) Verleden GM. Chronic allograft rejection (obliterative bronchiolitis). Semin Respir Crit Care Med. 2001;22:551-558.
(206.) Myers JL, Veal CF Jr, Shin MS, Katzenstein AL. Respiratory bronchiolitis causing interstitial lung disease: a clinicopathologic study of six cases. Am Rev Respir Dis. 1987;135:880-884.
(207.) Woo OH, Yong HS, Oh YW, Lee SY, Kim HK, Kang EY. Respiratory bronchiolitis-associated interstitial lung disease in a nonsmoker: radiologic and pathologic findings. AJR Am J Roentgenol. 2007;188:W412-W414.
(208.) Yousem SA, Colby TV, Gaensler EA. Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proc. 1989;64:1373-1380.
(209.) King TE Jr. Respiratory bronchiolitis-associated interstitial lung disease. Clin Chest Med. 1993;14:693-698.
(210.) Essadki O, Chartrand-Lefebvre C, Briere J, Grenier P. Respiratory bronchiolitis: radiographic and CT findings in a pathologically proven case. Eur Radiol. 1998;8:1674-1676.
(211.) Fraig M, Shreesha U, Savici D, Katzenstein AL. Respiratory bronchiolitis: a clinicopathologic study in current smokers, ex-smokers, and never-smokers. Am J Surg Pathol. 2002;26:647-653.
(212.) Park JS, Brown KK, Tuder RM, Hale VA, King TE Jr, Lynch DA. Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation. J Comput Assist Tomogr. 2002;26:13-20.
(213.) Vassallo R, Jensen EA, Colby TV, et al. The overlap between respiratory bronchiolitis and desquamative interstitial pneumonia in pulmonary Langerhans cell histiocytosis: high-resolution CT, histologic, and functional correlations. Chest. 2003;124:1199-1205.
(214.) Wells AU, Nicholson AG, Hansell DM, du Bois RM. Respiratory bronchiolitis-associated interstitial lung disease. Semin Respir Crit Care Med. 2003;24:585-594.
(215.) Craig PJ, Wells AU, Doffman S, et al. Desquamative interstitial pneumonia, respiratory bronchiolitis and their relationship to smoking. Histopathology. 2004;45:275-282.
(216.) Davies G, Wells AU, du Bois RM. Respiratory bronchiolitis associated with interstitial lung disease and desquamative interstitial pneumonia. Clin Chest Med. 2004;25:717-726, vi.
(217.) Ryu JH, Myers JL, Capizzi SA, Douglas WW, Vassallo R, Decker PA. Desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease. Chest. 2005;127:178-184.
(218.) Cordeirol CR, Freitas S, Rodrigues B, et al. Diagnosis of respiratory bronchiolitis associated interstitial lung disease. Monaldi Arch Chest Dis. 2006; 65:96-101.
(219.) Yousem SA. Respiratory bronchiolitis-associated interstitial lung disease with fibrosis is a lesion distinct from fibrotic nonspecific interstitial pneumonia: a proposal. Mod Pathol. 2006;19:1474-1479.
(220.) Portnoy J, Veraldi KL, Schwarz MI, et al. Respiratory bronchiolitis-interstitial lung disease: long-term outcome. Chest. 2007;131:664-671.
(221.) Churg A, Wright JL. Small-airway lesions in patients exposed to nonasbestos mineral dusts. Hum Pathol. 1983;14:688-693.
(222.) Gruden JF, Webb WR. CT findings in a proved case of respiratory bronchiolitis. AJR Am J Roentgenol. 1993;161:44-46.
(223.) Holt RM, Schmidt RA, Godwin JD, Raghu G. High resolution CT in respiratory bronchiolitis-associated interstitial lung disease. J Comput Assist Tomogr. 1993;17:46-50.
(224.) Heyneman LE, Ward S, Lynch DA, Remy-Jardin M, Johkoh T, Muller NL. Respiratory bronchiolitis, respiratory bronchiolitis-associated interstitial lung disease, and desquamative interstitial pneumonia: different entities or part of the spectrum of the same disease process? AJR Am J Roentgenol. 1999;173:1617-1622.
(225.) Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J. 2006;27:1272-1285.
(226.) Allen TC. Pulmonary Langerhans cell histiocytosis and other pulmonary histiocytic diseases: a review. Arch Pathol Lab Med. 2008;132:1171-1181.
(227.) Coleman A, Colby TV. Histologic diagnosis of extrinsic allergic alveolitis. Am J Surg Pathol. 1988;12:514-518.
(228.) Barrios RJ. Hypersensitivity pneumonitis: histopathology. Arch Pathol Lab Med. 2008;132:199-203.
(229.) Fraire AE. Hypersensitivity pneumonitis: a commentary. Arch Pathol Lab Med. 2008;132:192-194.
(230.) Madison JM. Hypersensitivity pneumonitis: clinical perspectives. Arch Pathol Lab Med. 2008;132:195-198.
(231.) Woda BA. Hypersensitivity pneumonitis: an immunopathology review. Arch Pathol Lab Med. 2008;132:204-205.
(232.) Seaton A, Lapp NL. Small airways disease in coalworkers' pneumoconiosis. Rev Inst Hyg Mines (Hasselt). 1974;29:51-54.
(233.) Bugalho de Almeida AA, Schott D, Zimmermann I, Ulmer WT. Pulmonary haemodynamics in coal workers' pneumoconiosis and non-p|neumoconiotic patients with chronic obstructive airways disease. Respiration. 1980; 40:31-37.
(234.) Churg A, Wright JL. Small airways disease and mineral dust exposure. Pathol Annu. 1983;18(pt 2):233-251.
(235.) Cohen BM, Adasczik A, Cohen EM. Small airways changes in workers exposed to asbestos. Respiration. 1984;45:296-302.
(236.) Wright JL, Churg A. Morphology of small-airway lesions in patients with asbestos exposure. Hum Pathol. 1984;15:68-74.
(237.) Churg A, Wright JL, Wiggs B, Pare PD, Lazar N. Small airways disease and mineral dust exposure: prevalence, structure, and function. Am Rev Respir Dis. 1985;131:139-143.
(238.) Kennedy SM, Wright JL, Mullen JB, Pare PD, Hogg JC. Pulmonary function and peripheral airway disease in patients with mineral dust or fume exposure. Am Rev Respir Dis. 1985;132:1294-1249.
(239.) Miller A. Small airway changes in workers exposed to asbestos. Respiration. 1985;48:190-191.
(240.) Dossing M, Groth S, Vestbo J, Lyngenbo O. Small-airways dysfunction in never smoking asbestos exposed Danish plumbers. Int Arch Occup Environ Health. 1990;62:209-212.
(241.) Pearson MG. Asbestos exposure and airways obstruction. Respir Med. 1991;85:344-346.
(242.) Chia KS, Ng TP, Jeyaratnam J. Small airways function of silica-exposed workers. Am J Ind Med. 1992;22:155-162.
(243.) Hu YB, Li QL, Jia YM, Wang Y, Chen DM, Hu TX. Pneumoconiosis: the changes of peripheral airways. Biomed Environ Sci. 1993;6:399-404.
(244.) Wright JL. Inhalational lung injury causing bronchiolitis. Clin Chest Med. 1993;14:635-644.
(245.) Kilburn KH, Warshaw RH. Airways obstruction from asbestos exposure: effects of asbestosis and smoking. Chest. 1994;106:1061-1070.
(246.) Jones RN, Glindmeyer HW III, Weill H. Review of the Kilburn and Warshaw Chest article--airways obstruction from asbestos exposure. Chest. 1995;107:1727-1729.
(247.) Kilburn KH, Warshaw RH. Airways obstruction from asbestos exposure and asbestosis revisited. Chest. 1995;107:1730-1731.
(248.) Sjogren B, Ljunggren KG, Almkvist O, Frech W, Basun H. A follow-up study of five cases of aluminosis. Int Arch Occup Environ Health. 1996;68:161-164.
(249.) Zejda JE. Occupational exposure to dusts containing asbestos and chronic airways disease. Int J Occup Med Environ Health. 1996;9:117-125.
(250.) Kampalath BN, McMahon JT, Cohen A, Tomashefski JF Jr, Kleinerman J. Obliterative central bronchitis due to mineral dust in patients with pneumoconiosis. Arch Pathol Lab Med. 1998;122:56-62.
(251.) Wright JL. Diseases of the small airways. Lung. 2001;179:375-396.
(252.) Churg A, Wright JL. Airway wall remodeling induced by occupational mineral dusts and air pollutant particles. Chest. 2002;122:306S-309S.
(253.) Delpierre S, Delvolgo-Gori MJ, Faucher M, Jammes Y. High prevalence of reversible airway obstruction in asbestos-exposed workers. Arch Environ Health. 2002;57:441-445.
(254.) Adelroth E, Hedlund U, Blomberg A, et al. Airway inflammation in iron ore miners exposed to dust and diesel exhaust. Eur Respir J. 2006;27:714-719.
(255.) Oliver LC, Miracle-McMahill H. Airway disease in highway and tunnel construction workers exposed to silica. Am J Ind Med. 2006;49:983-996.
(256.) Kreiss K. Occupational bronchiolitis obliterans masquerading as COPD. Am J Respir Crit Care Med. 2007;176:427-429.
(257.) Ansari HA, Al-Bahrani G, Vishwanath M, Prescott M, James J. Thoracic scintigraphy in aluminosis: lymph node uptake on bone scan. Clin Nucl Med. 2009;34:24-26.
(258.) Darke CS, Warrack AJ. Bronchiolitis from nitrous fumes. Thorax. 1958; 13:327-333.
(259.) Milne JE. Nitrogen dioxide inhalation and bronchiolitis obliterans: a review of the literature and report of a case. J Occup Med. 1969;11:538-547.
(260.) Mitchell CA, Gandevia B. Acute bronchiolitis following provocative inhalation of "alcalase"--a proteolytic enzyme used in the detergent industry. Med J Aust. 1971;1:1363-1367.
(261.) Perez-Guerra F, Walsh RE, Sagel SS. Bronchiolitis obliterans and tracheal stenosis: late complications of inhalation burn. JAMA. 1971;218:1568-1570.
(262.) Sobonya R. Fatal anhydrous ammonia inhalation. Hum Pathol. 1977;8: 293-299.
(263.) Kirkpatrick MB, Bass JB. Severe obstructive lung disease after smoke inhalation. Chest. 1979;76:108-110.
(264.) Woodford DM, Coutu RE, Gaensler EA. Obstructive lung disease from acute sulfur dioxide exposure. Respiration. 1979;38:238-245.
(265.) Arora NS, Aldrich TK. Bronchiolitis obliterans from a burning automobile. South Med J. 1980;73:507-510.
(266.) Price SK, Hughes JE, Morrison SC, Potgieter PD. Fatal ammonia inhalation: a case report with autopsy findings. S Afr Med J. 1983;64:952-955.
(267.) Seggev JS, Mason UG III, Worthen S, Stanford RE, Fernandez E. Bronchiolitis obliterans: report of three cases with detailed physiologic studies. Chest. 1983;83:169-174.
(268.) Matarese SL, Matthews JI. Zinc chloride (smoke bomb) inhalational lung injury. Chest. 1986;89:308-309.
(269.) Weill H. Disaster at Bhopal: the accident, early findings and respiratory health outlook in those injured. Bull Eur Physiopathol Respir. 1987;23:587-590.
(270.) Ducatman AM, Ducatman BS, Barnes JA. Lithium battery hazard: old-fashioned planning implications of new technology. J Occup Med. 1988;30:309- 311.
(271.) Kraut A, Lilis R. Chemical pneumonitis due to exposure to bromine compounds. Chest. 1988;94:208-210.
(272.) Lee MJ, O'Connell DJ. The plain chest radiograph after acute smoke inhalation. Clin Radiol. 1988;39:33-37.
(273.) Konichezky S, Schattner A, Ezri T, Bokenboim P, Geva D. Thionylchloride-induced lung injury and bronchiolitis obliterans. Chest. 1993;104:971- 973.
(274.) Weiss SM, Lakshminarayan S. Acute inhalation injury. Clin Chest Med. 1994;15:103-116.
(275.) do Pico GA. Toxic gas inhalation. Curr Opin Pulm Med. 1995;1:102-108.
(276.) Vijayan VK, Sankaran K, Sharma SK, Misra NP. Chronic lung inflammation in victims of toxic gas leak at Bhopal. Respir Med. 1995;89:105-111.
(277.) Janigan DT, Kilp T, Michael R, McCleave JJ. Bronchiolitis obliterans in a man who used his wood-burning stove to burn synthetic construction materials. CMAJ. 1997;156:1171-1173.
(278.) Beckett WS. Persistent respiratory effects in survivors of the Bhopal disaster. Thorax. 1998;53(suppl 2):S43-S46.
(279.) Boag AH, Colby TV, Fraire AE, et al. The pathology of interstitial lung disease in nylon flock workers. Am J Surg Pathol. 1999;23:1539-1545.
(280.) Asano S, Eto K, Kurisaki E, et al. Review article: acute inorganic mercury vapor inhalation poisoning. Pathol Int. 2000;50:169-174.
(281.) Kern DG, Kuhn C, 3rd, Ely EW, et al. Flock worker's lung: broadening the spectrum of clinicopathology, narrowing the spectrum of suspected etiologies. Chest. 2000;117:251-259.
(282.) Schachter EN, Zuskin E, Saric M. Occupational airway diseases. Rev Environ Health. 2001;16:87-95.
(283.) Thomason JW, Rice TW, Milstone AP. Bronchiolitis obliterans in a survivor of a chemical weapons attack. JAMA. 2003;290:598-599.
(284.) Dompeling E, Jobsis Q, Vandevijver NM, Wesseling G, Hendriks H. Chronic bronchiolitis in a 5-yr-old child after exposure to sulphur mustard gas. Eur Respir J. 2004;23:343-346.
(285.) Ghanei M, Fathi H, Mohammad MM, Aslani J, Nematizadeh F. Long-term respiratory disorders of claimers with subclinical exposure to chemical warfare agents. Inhal Toxicol. 2004;16:491-495.
(286.) Ghanei M, Mokhtari M, Mohammad MM, Aslani J. Bronchiolitis obliterans following exposure to sulfur mustard: chest high resolution computed tomography. Eur J Radiol. 2004;52:164-169.
(287.) Parimon T, Kanne JP, Pierson DJ. Acute inhalation injury with evidence of diffuse bronchiolitis following chlorine gas exposure at a swimming pool. Respir Care. 2004;49:291-294.
(288.) Bonetto G, Corradi M, Carraro S, et al. Longitudinal monitoring of lung injury in children after acute chlorine exposure in a swimming pool. Am J Respir Crit Care Med. 2006;174:545-549.
(289.) Harber P, Saechao K, Boomus C. Diacetyl-induced lung disease. Toxicol Rev. 2006;25:261-272.
(290.) Antonini JM, Stone S, Roberts JR, et al. Effect of short-term stainless steel welding fume inhalation exposure on lung inflammation, injury, and defense responses in rats. Toxicol Appl Pharmacol. 2007;223:234-245.
(291.) Ghio AJ, Turi JL, Madden MC, et al. Lung injury after ozone exposure is iron dependent. Am J Physiol Lung Cell Mol Physiol. 2007;292:L134-L143.
(292.) Nambiar MP, Gordon RK, Rezk PE, et al. Medical countermeasure against respiratory toxicity and acute lung injury following inhalation exposure to chemical warfare nerve agent VX. Toxicol Appl Pharmacol. 2007;219:142-150.
(293.) Raulf-Heimsoth M, Pesch B, Schott K, et al. Irritative effects of fumes and aerosols of bitumen on the airways: results of a cross-shift study. Arch Toxicol. 2007;81:35-44.
(294.) Benomran FA, Hassan AI, Masood SS. Accidental fatal inhalation of sulfuric acid fumes. J Forensic Leg Med. 2008;15:56-58.
(295.) Antonini JM, Roberts JR, Stone S, Chen BT, Schwegler-Berry D, Frazer DG. Short-term inhalation exposure to mild steel welding fume had no effect on lung inflammation and injury but did alter defense responses to bacteria in rats. Inhal Toxicol. 2009;21:182-192.
(296.) Kanwal R. Severe occupational lung disease from exposure to flavoring chemicals. Am Fam Physician. 2009;79:87.
(297.) Padley SP, Adler B, Hansell DM, Muller NL. High-resolution computed tomography of drug-induced lung disease. Clin Radiol. 1992;46:232-236.
(298.) Ellis SJ, Cleverley JR, Muller NL. Drug-induced lung disease: high-resolution CT findings. AJR Am J Roentgenol. 2000;175:1019-1024.
(299.) Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Muller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol. 2002;57: 292-299.
(300.) Erasmus JJ, McAdams HP, Rossi SE. High-resolution CT of drug-induced lung disease. Radiol Clin North Am. 2002;40:61-72.
(301.) Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med. 2004;25:25-35.
(302.) Flieder DB, Travis WD. Pathologic characteristics of drug-induced lung disease. Clin Chest Med. 2004;25:37-45.
(303.) Meltzer E, Guranda L, Perelman M, Krupsky M, Vassilenko L, Sidi Y. Lipoid pneumonia: a preventable form of drug-induced lung injury.
Eur J Intern Med. 2005;16:615-617.
(304.) Silva CI, Muller NL. Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations. Semin Ultrasound CT MR. 2006;27:111-116.
(305.) Romagnoli M, Bigliazzi C, Casoni G, et al. The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25:36-45.
(306.) Churg A, Myers J, Suarez T, et al. Airway-centered interstitial fibrosis: a distinct form of aggressive diffuse lung disease. Am J Surg Pathol. 2004;28:62-68.
(307.) Colombat M, Groussard O, Taille C, et al. Lung transplantation in a patient with airway-centered fibrosis. Am J Surg Pathol. 2004;28:1540-1542.
(308.) Fenton ME, Cockcroft DW, Wright JL, Churg A. Hypersensitivity pneumonitis as a cause of airway-centered interstitial fibrosis. Ann Allergy Asthma Immunol. 2007;99:465-466.
(309.) Serrano M, Molina-Molina M, Ramirez J, Sanchez M, Xaubet A. Airway-centered interstitial fibrosis related to exposure to fumes from cleaning products [in Spanish]. Arch Bronconeumol. 2006;42:557-559.
(310.) Xu L, Cai BQ, Liu HR, Zhu YJ. Diagnosis and differential diagnosis of airway-centered interstitial fibrosis [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005;27:99-102.
(311.) Yi XH, Cheng XM, Li HP. Airway-centered interstitial fibrosis [in Chinese]. Zhonghua Bing Li Xue Za Zhi. 2005;34:755-756.
(312.) Yi XH, Chu HQ, Cheng XM, Luo BF, Li HP. Idiopathic airway-centered interstitial fibrosis: report of two cases. Chin Med J (Engl). 2007;120:847-850.
(313.) Yousem SA, Dacic S. Idiopathic bronchiolocentric interstitial pneumonia. Mod Pathol. 2002;15:1148-1153.
(314.) Munoz A, Aranda I, Pascual J, Ferrando C. Idiopathic bronchiolocentric interstitial pneumonia: a new idiopathic interstitial pneumonia [in Spanish]. Arch Bronconeumol. 2007;43:464-466.
(315.) Fukuoka J, Franks TJ, Colby TV, et al. Peribronchiolar metaplasia: a common histologic lesion in diffuse lung disease and a rare cause of interstitial lung disease: clinicopathologic features of 15 cases. Am J Surg Pathol. 2005;29: 948-954.
(316.) Lai RS, Chiang AA, Wu MT, et al. Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Taiwan. Lancet. 1996; 348:83-85.
(317.) Lin TJ, Lu CC, Chen KW, Deng JF. Outbreak of obstructive ventilatory impairment associated with consumption of Sauropus androgynus vegetable. J Toxicol Clin Toxicol. 1996;34:1-8.
(318.) Roggli VL, Chiang A. Constrictive bronchiolitis obliterans in Sauropus androgynus poisoning. J Toxicol Clin Toxicol. 1996;34:525-528.
(319.) Chang H, Wang JS, Tseng HH, Lai RS, Su JM. Histopathological study of Sauropus androgynus-associated constrictive bronchiolitis obliterans: a new cause of constrictive bronchiolitis obliterans. Am J Surg Pathol. 1997;21:35-42.
(320.) Ger LP, Chiang AA, Lai RS, Chen SM, Tseng CJ. Association of Sauropus androgynus and bronchiolitis obliterans syndrome: a hospital-based case-control study. Am J Epidemiol. 1997;145:842-849.
(321.) Wu CL, Hsu WH, Chiang CD, et al. Lung injury related to consuming Sauropus androgynus vegetable. J Toxicol Clin Toxicol. 1997;35:241-248.
(322.) Yang CF, Wu MT, Chiang AA, et al. Correlation of high-resolution CT and pulmonary function in bronchiolitis obliterans: a study based on 24 patients associated with consumption of Sauropus androgynus. AJR Am J Roentgenol. 1997;168:1045-1050.
(323.) Chang YL, Yao YT, Wang NS, Lee YC. Segmental necrosis of small bronchi after prolonged intakes of Sauropus androgynus in Taiwan. Am J Respir Crit Care Med. 1998;157:594-598.
(324.) Hsu H, Chang H, Su J, Goan Y, Wong C, Huang M. Lung transplantation in Sauropus androgynus consumption patients in Taiwan. Transplant Proc. 1998; 30:3393-3394.
(325.) Vartanian RK. Sauropus bronchiolitis. Am J Surg Pathol. 1998;22:380-381.
(326.) Wu CL, Hsu WH, Chiang CD. The effect of large-dose prednisolone on patients with obstructive lung disease associated with consuming Sauropus androgynus. Zhonghua Yi Xue Za Zhi (Taipei). 1998;61:34-38.
(327.) Luh SP, Lee YC, Chang YL, Wu HD, Kuo SH, Chu SH. Lung transplantation for patients with end-stage Sauropus androgynus-induced bronchiolitis obliterans (SABO) syndrome. Clin Transplant. 1999;13:496-503.
(328.) Chang YL, Chen JS, Wu HD, Lee YC. Retransplantation of contralateral lung in a patient with Sauropus androgynus-induced bronchobronchiolitis obliterans. Transplant Proc. 2000;32:2432-2434.
(329.) Hsu H, Chang H, Goan Y. Intermediate results in Sauropus androgynus bronchiolitis obliterans patients after single-lung transplantation. Transplant Proc. 2000;32:2422-2423.
(330.) Wang JS, Tseng HH, Lai RS, Hsu HK, Ger LP. Sauropus androgynus-constrictive obliterative bronchitis/bronchiolitis--histopathological study of pneumonectomy and biopsy specimens with emphasis on the inflammatory process and disease progression. Histopathology. 2000;37:402-410.
(331.) Oonakahara K, Matsuyama W, Higashimoto I, et al. Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Japan--alert of food-associated pulmonary disorders from Japan. Respiration. 2005;72:221.
(332.) Oonakahara K, Matsuyama W, Higashimoto I, et al. Living-donor lobar lung transplantation in Sauropus androgynus-associated bronchiolitis obliterans in Japan. Intern Med. 2005;44:1103-1104.
(333.) Hayashi M, Tagawa A, Ogura T, et al. Familial occurrence of bronchiolitis obliterans associated with Sauropus androgynus [in Japanese]. Nihon Kokyuki Gakkai Zasshi. 2007;45:81-86.
(334.) Yu Swee Y, Cheah Chooi H. Nutritive value and toxicity of Sauropus albicans, a Malaysian leafy vegetable. Food Nutr (Roma). 1979;5:38.
(335.) Chen IC, Chang KC, Hsieh YK, Wu D. Torsade de pointes due to consumption of Sauropus androgynus as a weight-reducing vegetable. Am J Cardiol. 1996;78:1186-1187.
(336.) Hsiue TR, Guo YL, Chen KW, Chen CW, Lee CH, Chang HY. Dose-response relationship and irreversible obstructive ventilatory defect in patients with consumption of Sauropus androgynus. Chest. 1998;113:71-76.
(337.) Mark EJ, Ruangchira-urai R. Bronchiolitis interstitial pneumonitis: a pathologic study of 31 lung biopsies with features intermediate between bronchiolitis obliterans organizing pneumonia and usual interstitial pneumonitis, with clinical correlation. Ann Diagn Pathol. 2008;12:171-180.
* References 39, 42-49, 52, 55, 61, 63, 64, 66.
([dagger]) References 39, 42, 43, 47, 52, 54-56, 62, 64, 66.
([double dagger]) References 42-44, 47, 52, 53, 55, 56, 59, 60, 73-79.
([section]) References 116-118, 120-126, 131-133.
** References 29, 122, 123, 125, 126, 136-138.
([dagger])(dagger) References 122, 125, 126, 131, 139-142.
([double dagger])([double dagger]) References 29, 39, 156-178, 180, 181, 184-186.
([section])([section]) References 29, 39, 156-177, 179-181, 185, 187, 188.
*** References 11, 15, 29, 39, 67, 71, 84, 189-203.
([dagger])([dagger])([dagger]) References 29, 39, 67, 71, 189, 190, 192-194, 204, 205.
([double dagger])([double dagger])([double dagger]) References 14, 29, 38, 39, 206-220.
([section])([section])([section]) References 14, 206-208, 210, 212, 222-224.
**** References 29, 39, 67, 234, 236, 237, 239, 241, 244, 248, 250- 252, 254-257.
([dagger])([dagger])([dagger])([dagger]) References 29, 39, 196, 197, 201, 244, 258-296.
([double dagger])([double dagger])([double dagger])([double dagger]) References 29, 39, 196, 197, 201, 244, 261, 263, 265, 267, 268, 271, 273, 274, 279-281, 283, 284, 286-296.
Timothy Craig Allen, MD, JD
Accepted for publication September 8, 2009.
From the Department of Pathology, The University of Texas Health Science Center at Tyler.
The author has no relevant financial interest in the products or companies described in this article.
Reprints: Timothy Craig Allen, MD, JD, Department of Pathology, The University of Texas Health Science Center at Tyler, 11937 Highway 271, Tyler, TX 75708-3154 (e-mail: email@example.com).
Table 1. Classification of Small Airways Disease, 1993 (a) Acute (infectious) bronchiolitis Bronchiolitis obliterans-organizing pneumonia; cryptogenic organizing pneumonia Constrictive (obliterative) bronchiolitis; bronchiolitis obliterans Adult bronchiolitis Respiratory (smoker's) bronchiolitis-associated interstitial lung disease Mineral dust airways disease Follicular bronchiolitis Diffuse panbronchiolitis (a) Data were derived from Myers and Colby. (23) Table 2. Classification of Small Airways Disease, 2006 (a) Cellular bronchiolitis Constrictive bronchiolitis obliterans Nonspecific chronic bronchiolitis Respiratory (smoker's) bronchiolitis Follicular bronchiolitis Diffuse panbronchiolitis (a) Data were derived from Katzenstein. (27) Table 3. Classification of Small Airways Disease, 2008 (a) Cellular bronchiolitis Acute bronchiolitis Acute and chronic bronchiolitis Chronic bronchiolitis, with or without fibrosis Subtypes of cellular bronchiolitis Follicular bronchiolitis Diffuse panbronchiolitis Bronchiolitis obliterans with intraluminal polyps Constrictive bronchiolitis Respiratory bronchiolitis Mineral dust-associated airway disease Peribronchiolar metaplasia Bronchiolocentric nodules Asthmatic-type changes Chronic bronchitis/emphysema-associated small airways changes (a) Data were derived from Cagle et al. (39) Table 4. Potential Etiologies of Acute Bronchiolitis (a) Viral infection Bacterial infection Acute exposure to fumes and toxins Local changes of acute bronchopneumonia Wegener granulomatosis (rarely) (a) Data were derived from Cagle et al. (39) Table 5. Potential Etiologies of Acute and Chronic Bronchiolitis (a) Viral infection Bacterial infection Mycoplasma infection Hypersensitivity pneumonitis Respiratory bronchiolitis Aspiration pneumonia Pulmonary involvement with collagen vascular disease Posttransplantation, graft-versus-host disease Wegener granulomatosis Bronchocentric granulomatosis Diffuse panbronchiolitis Inhalation of fumes and toxins Asthma Inflammatory bowel disease-related small airways disease Idiopathic (a) Data were derived from Cagle et al. (39) Table 6. Potential Etiologies of Chronic Bronchiolitis (a) Infection Collagen vascular disease Posttransplantation graft-versus-host disease Inflammatory bowel disease-related small airways disease Hypersensitivity pneumonitis Pulmonary Langerhans cell histiocytosis Aspiration pneumonia Diffuse panbronchiolitis Distal to bronchiectasis Lymphoproliferative disorders Local inflammatory reaction such as with middle lobe syndrome Asthma Chronic obstructive pulmonary disease Idiopathic (a) Data were derived from Cagle et al.39 Table 7. Potential Etiologies of Bronchiolar Necrosis (a) Viral infections Adenovirus Herpes virus Influenza Bronchocentric fungal infections Bacterial infections Bronchocentric granulomatosis Exposure to fumes and toxins Wegener granulomatosis (a) Data were derived from Cagle et al. (39) Table 8. Potential Etiologies of Granulomatous Bronchiolitis (a) Fungal infections Mycobacterial infections, including atypical mycobacterial infections Hypersensitivity pneumonitis Sarcoidosis Aspiration pneumonia Bronchocentric granulomatosis Crohn disease Wegener granulomatosis Hard metal disease (a) Data were derived from Cagle et al. (39) Table 9. Potential Etiologies of Organizing Pneumonia With Intraluminal Polyps (a) Diffuse alveolar damage, organizing Aspiration pneumonia, organizing Resolving infections Postobstruction organization Hypersensitivity pneumonitis Organization after exposure to fumes and toxins Collagen vascular disease Acute lung transplant rejection Drug reactions Secondary to bone marrow transplantation or other organ transplantation Reaction to radiation therapy or chemotherapy Chronic eosinophilic pneumonia Secondary reaction with chronic bronchiolitis Reparative process adjacent to abscess, necrotic tumor, infarct, etc Secondary to a hematologic disorder Inflammatory bowel disease-related small airways disease Wegener granulomatosis Idiopathic (a) Data were derived from Cagle et al. (39) Table 10. Potential Etiologies of Constrictive Bronchiolitis (a) Post lung transplantation Post bone marrow transplantation Healed infection, especially adenovirus infection Drug reactions Healed injury from exposure to fumes and toxins Collagen vascular disease, especially rheumatoid arthritis As a component or complication of: Bronchiectasis Cellular bronchiolitis Asthma Chronic bronchitis Cystic fibrosis DIPNECH or carcinoid tumorlets Inflammatory bowel disease-associated small airways disease Idiopathic Abbreviation: DIPNECH, diffuse idiopathic neuroendocrine cell hyperplasia. (a) Data derived from Cagle et al. (39)
|Printer friendly Cite/link Email Feedback|
|Author:||Allen, Timothy Craig|
|Publication:||Archives of Pathology & Laboratory Medicine|
|Date:||May 1, 2010|
|Previous Article:||Update on nonneoplastic pulmonary lymphoproliferative disorders and related entities.|
|Next Article:||The pathologist's approach to acute lung injury.|